| Literature DB >> 30652742 |
Ünsal Vural1, Ahmet Yavuz Balcı1, Ahmet Arif Ağlar1, Mehmet Kızılay1.
Abstract
OBJECTIVE: The effects of energy source on the maintenance of sinus rhythm and the contribution of demographic characteristics to the case selection in patients submitted to ablation performed concurrently with mitral valve surgery were analyzed.Entities:
Mesh:
Year: 2018 PMID: 30652742 PMCID: PMC6326442 DOI: 10.21470/1678-9741-2018-0130
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Demographical characteristics of the cases
| Ablation type | ||||||
|---|---|---|---|---|---|---|
| RFA (n=54) | CrA (n=42) | |||||
| Mean | SD | Mean | SD | |||
| Age (years) | 48 | 9 | 53 | 9 | 0.016 | |
| Left atrium diameter (mm) | 48.98 | 5.45 | 49.05 | 5.72 | 0.954 | |
| Intensive Care Unit (days) | 1 | 1 | 1 | __ | 0.145 | |
| Hospitalization (days) | 6 | 1 | 6 | 1 | 0.509 | |
| Aortic cross-clamping time (min) | 63 | 12 | 68 | 11 | 0.035 | |
| Total cardiopulmonary bypass time (min) | 66 | 10 | 83 | 10 | 0.001 | |
| Left ventricular ejection fraction (%) | 48.78 | 6.52 | 50.07 | 6.13 | 0.325 | |
| Preoperative CRP (mg/dL) | 4.6 | 1.6 | 4.5 | 1.5 | 0.864 | |
| Body mass index (kg/m2) | <25 | 25 | 54.3 | 21 | 45.7 | 0.395 |
| 25-29 | 20 | 55.6 | 16 | 44.4 | ||
| 30-35 | 6 | 54.5 | 5 | 45.5 | ||
| >35 | 3 | 100 | __ | __ | ||
| Gender | Female | 24 | 48 | 26 | 52 | 0.089 |
| Male | 30 | 65.2 | 16 | 34.8 | ||
| Surgical procedure | MVR | 29 | 65.9 | 15 | 34.1 | 0.079 |
| MVR+TDVGA | 25 | 48.1 | 27 | 51.9 | ||
| Previous stroke | Unavailable | 52 | 55.9 | 41 | 44.1 | 0.712 |
| Available | 2 | 66.7 | 1 | 33.3 | ||
| Postoperative pacemaker | Unavailable | 53 | 55.8 | 42 | 44.2 | 0.375 |
| Available | 1 | 100 | __ | __ | ||
| Chronic obstructive pulmonary disease | Unavailable | 47 | 54.7 | 39 | 45.3 | 0.356 |
| Available | 7 | 70 | 3 | 30 | ||
| New York Heart Association functional class | I | 10 | 41.7 | 14 | 58.3 | 0.13 |
| II | 30 | 60 | 20 | 40 | ||
| III | 14 | 63.6 | 8 | 36.4 | ||
| IV | __ | __ | __ | __ | ||
| Hypertension | Unavailable | 45 | 55.6 | 36 | 44.4 | 0.75 |
| Available | 9 | 60 | 6 | 40 | ||
=independent t-test;
=Chi-square test; Fisher's exact test, continuity correction test.
CrA=cryoablation; MVR+TDVGA=mitral valve replacement+tricuspid De Vega annuloplasty; RFA=radiofrequency ablation; SD=standard deviation
Fig. 1Schematic drawing on ablation technique used in the study.
Fig. 2Survival analysis of cases according to the energy source used. AF=atrial fibrillation; CrA=cryothermal ablation; RFA=radiofrequency ablation
Distribution of risk parameters in relation to postoperative atrial fibrillation status.
| AF status | ||||||
|---|---|---|---|---|---|---|
| Unavailable | Available | |||||
| Mean | SD | Mean | SD | |||
| Age (years) | 50 | 9 | 50 | 10 | 0.921 | |
| Left atrium diameter (mm) | 48.1 | 5.11 | 54.36 | 5.06 | 0.001 | |
| Intensive Care Unit (days) | 1 | 1 | 1 | 1 | 0.685 | |
| Hospitalization (days) | 6 | 1 | 6 | 1 | 0.843 | |
| Aortic cross-clamping time (min) | 64 | 11 | 68 | 14 | 0.236 | |
| Cardiopulmonary bypass time (min) | 75 | 13 | 68 | 16 | 0.08 | |
| Left ventricular ejection fraction (%) | 50.44 | 5.85 | 42.93 | 5.46 | 0.001 | |
| Body mass index (kg/m2) | <25 | 46 | 100 | __ | __ | 0.001 |
| 25-29 | 27 | 75 | 9 | 25 | ||
| 30-35 | 9 | 81.8 | 2 | 18.2 | ||
| >35 | __ | __ | 3 | 100 | ||
| Gender | Woman | 43 | 86 | 7 | 14 | 0.872 |
| Man | 39 | 84.8 | 7 | 15.2 | ||
| Surgical procedure | MVR | 35 | 79.5 | 9 | 20.5 | 0.137 |
| MVR+TDVGA | 47 | 90.4 | 5 | 9.6 | ||
| Previous stroke | Unavailable | 79 | 84.9 | 14 | 15.1 | 0.472 |
| Available | 3 | 100 | __ | __ | ||
| Postoperative pacemaker | Unavailable | 81 | 85.3 | 14 | 14.7 | 0.682 |
| Available | 1 | 100 | __ | __ | ||
| Chronic obstructive pulmonary disease | Unavailable | 76 | 88.4 | 10 | 11.6 | 0.016 |
| Available | 6 | 60 | 4 | 40 | ||
| New York Heart Association functional class | I | 23 | 95.8 | 1 | 4.2 | 0.343 |
| II | 40 | 80 | 10 | 20 | ||
| III | 19 | 86.4 | 3 | 13.6 | ||
| IV | __ | __ | __ | __ | ||
| Hypertension | Unavailable | 74 | 91.4 | 7 | 8.6 | 0.001 |
| Available | 8 | 53.3 | 7 | 46.7 | ||
| Ablation type | RFA | 45 | 83.3 | 9 | 16.7 | 0.517 |
| CrA | 37 | 88.1 | 5 | 11.9 | ||
| CRP | Postoperative | 65.2 | 26.4 | 84.5 | 7.5 | 0.266 |
| 15th postoperative day | 9.3 | 6.9 | 16.4 | 8.9 | 0.003 | |
| 1st postoperative month | 2.7 | 1.2 | 5.1 | 1.0 | 0.001 | |
=independent t test;
=Chi-square, Fisher's exact test, continuity correction test
=for statistical analysis of AF recurrence, the data on the same day and month were taken into consideration.
MVR+TDVGA=mitral valve replacement +tricuspid De Vega annuloplasty; SD=standard deviation; AF=atrial fibrillation; CrA=cryothermal ablation; CRP=C-reactive protein; MVR=mitral valve replacement; RFA=radiofrequency ablation
Fig. 3a) Change in the recurrence of AF with left atrium diameter and LVEF. b, c, d) Survival analysis of postoperative COPD, BMI and hypertension with Mentel-Cox significance values. BMI=body mass index; COPD=chronic obstructive pulmonary disease; LA= eft atrium; LVEF=left ventricular ejection fraction
Fig. 6Factors correlated with AF recurrence after ablation (r correlation coefficient of significance at P<0.05 were taken). AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; CRP=C-reactive protein; LA=left atrium; LVEF=left ventricular ejection fraction
Fig. 5ROC curve analysis graphs of factors affecting AF recurrence. AF=atrial fibrillation; BMI=body mass index; LA=left atrium; LVEF=left ventricular ejection fraction
Fig. 4The change in CRP levels in relation to the cases with and without AF recurrence and the significance ratios according to Cox regression analysis. CRP=C-reactive protein
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ÜV | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| AYB | Final approval of the version to be published |
| AAA | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| MK | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |